105.44

0.69% 0.72

After Hours: 105.44

Protagonist Therapeutics Inc (PTGX)

Overview News Price History Option Chain Financials Why PTGX Down? Discussions Forecast

Protagonist Therapeutics Inc stock is traded at $105.44, with a volume of 770.16K. It is up +0.69% in the last 24 hours and up +14.16% over the past month. Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Previous Close:

$104.72

Open:

$105.96

24h Volume:

770.16K

Relative Volume:

0.98

Market Cap:

$6.73B

Revenue:

$46.02M

Net Income/Loss:

$-130.15M

P/E Ratio:

-51.62

EPS:

-2.0427

Net Cash Flow:

$56.08M

1W Performance:

+3.28%

1M Performance:

+14.16%

6M Performance:

+35.74%

1Y Performance:

+124.58%

1-Day Range:

$103.02

$106.66

1-Week Range:

$95.40

$106.66

52-Week Range:

$41.28

$107.84

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name

Protagonist Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(510) 474-0170

Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Employee

132

Twitter

Next Earnings Date

2026-02-20

Latest SEC Filings

PTGX's Discussions on Twitter

Compare PTGX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PTGX Protagonist Therapeutics Inc	105.44	6.68B	46.02M	-130.15M	56.08M	-2.0427
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Barclays	Overweight
Sep-12-25	Initiated	Leerink Partners	Outperform
Jun-17-25	Initiated	Citigroup	Buy
Dec-06-24	Initiated	BMO Capital Markets	Outperform
Dec-06-24	Initiated	Goldman	Neutral
Nov-05-24	Initiated	Wedbush	Outperform
Sep-24-24	Initiated	TD Cowen	Buy
Sep-09-24	Initiated	Truist	Buy
Oct-30-23	Initiated	CapitalOne	Overweight
May-25-23	Resumed	Jefferies	Buy
Aug-25-22	Initiated	JMP Securities	Mkt Outperform
Feb-11-22	Initiated	BTIG Research	Buy
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral
May-24-21	Initiated	JMP Securities	Mkt Outperform
May-24-21	Initiated	Northland Capital	Outperform
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight
Sep-18-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Initiated	Jefferies	Buy
May-18-20	Reiterated	H.C. Wainwright	Buy
Jul-08-19	Initiated	H.C. Wainwright	Buy
May-09-19	Upgrade	Stifel	Hold → Buy
Dec-06-18	Initiated	Nomura	Buy
Jan-29-18	Initiated	Stifel	Buy
Jul-21-17	Initiated	BTIG Research	Buy

View All

Protagonist Therapeutics Inc Stock (PTGX) Latest News

01:48 AM

PTGX Maintained by Truist Securities -- Price Target Raised to $121 - GuruFocus

01:48 AM

01:37 AM

Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN

01:37 AM

10:40 AM

Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics - Barchart.com

10:40 AM

09:07 AM

Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $121 - Moomoo

09:07 AM

Apr 14, 2026

Protagonist Therapeutics (PTGX) price target increased by 11.65% to 114.50 - MSN

Apr 14, 2026

Jefferies reiterates Protagonist Therapeutics stock rating on Icotyde outlook By Investing.com - Investing.com Canada

Apr 14, 2026

Protagonist Therapeutics Jumps 7.0% in Broad Rally - AlphaStreet

Apr 14, 2026

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com - Investing.com South Africa

Apr 14, 2026

Truist raises Protagonist Therapeutics stock price target on Icotyde outlook - Investing.com

Apr 14, 2026

Apr 11, 2026

Trading Systems Reacting to (PTGX) Volatility - Stock Traders Daily

Apr 11, 2026

Apr 10, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 10, 2026

Apr 09, 2026

PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill

Apr 09, 2026

Apr 08, 2026

Maintained Buy: Jefferies and Johnson Rice on Protagonist Therapeutics (PTGX) March 2026 - Meyka

Apr 08, 2026

PTGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

AI Stocks: Is Protagonist Therapeutics Inc forming a bullish divergence2026 Chart Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Investor Mood: Will Protagonist Therapeutics Inc benefit from rate cuts2026 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn

Apr 07, 2026

Is Protagonist Therapeutics Inc stock good for income investors2026 Macro Moves & Daily Stock Momentum Reports - baoquankhu1.vn

Apr 07, 2026

Protagonist Therapeutics Price Target Raised to $116.00/Share From $104.00 by Clear Street - Moomoo

Apr 07, 2026

PTGX: Clear Street Raises Price Target for Protagonist Therapeutics | PTGX Stock News - GuruFocus

Apr 07, 2026

Apr 06, 2026

Clear Street Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $116 - Moomoo

Apr 06, 2026

Clear Street raises Protagonist Therapeutics price target on drug potential By Investing.com - Investing.com India

Apr 06, 2026

Clear Street raises Protagonist Therapeutics price target on drug potential - Investing.com

Apr 06, 2026

SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Apr 06, 2026

Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN

Apr 06, 2026

Apr 05, 2026